Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin
esmo - Findings from the KEYNOTE-905/EV-303 study
AI Summary: KEYNOTE‑905/EV‑303 results show perioperative enfortumab vedotin combined with pembrolizumab significantly improved event‑free survival, overall survival and pathological complete response in muscle‑invasive bladder cancer patients ineligible for cisplatin. The findings could shift neoadjuvant strategies for this high‑risk group and spur guideline updates and broader adoption in practice.
Related Stories
Belzutifan combinations highlighted at ASCO GU improve RCC outcomes / 4 months
Rezatapopt shows proof-of-concept reactivating mutant p53 in patients / 4 months
TTLC 2026 highlights advanced NSCLC symposia and emerging data / 4 months
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival / 3 months
HORMAD1 emerges as a potential target in triple‑negative breast cancer / 3 months
Roche’s hoped‑for breast cancer pill fails crucial first‑line trial / 3 months
Romiplostim prevents chemo-induced platelet crashes in phase 3 trial / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Hospital Operations, Avian Influenza, Pharmaceuticals, Drug Development and look for the RSS link.
StackHealth Time Machine